Debates between Baroness Jones of Whitchurch and Lord Patel during the 2024 Parliament

Medical Product Liability

Debate between Baroness Jones of Whitchurch and Lord Patel
Wednesday 16th October 2024

(1 month, 1 week ago)

Lords Chamber
Read Full debate Read Hansard Text Read Debate Ministerial Extracts
Baroness Jones of Whitchurch Portrait Baroness Jones of Whitchurch (Lab)
- View Speech - Hansard - -

My Lords, we very much welcome the appointment of Dr Henrietta Hughes as the Patient Safety Commissioner. We have been looking at the details of her work and hope to come back in due course, particularly on the report that she produced in February. I understand that my noble friend Lady Merron has already met the Patient Safety Commissioner; she has been on a joint visit with her and plans to meet her again in the future.

Lord Patel Portrait Lord Patel (CB)
- View Speech - Hansard - - - Excerpts

My Lords, there are over 600,000 medical devices used in the United Kingdom. Worldwide, there are probably over 2 million medical devices being used. People obviously want the devices as soon as they are available on the market without having been tested medically first. I am pleased to hear the Minister say that the Government intend to review the legislation, particularly as it applies to class 3 devices; they are mostly implant devices and cause most of the damage, including the mesh and other implanted devices. Can the Minister confirm that the Government will look in a stratified way as to where the legislation should apply and to what category of device?

Baroness Jones of Whitchurch Portrait Baroness Jones of Whitchurch (Lab)
- View Speech - Hansard - -

My Lords, we have already done considerable work on this, and I pay tribute to the noble Baroness, Lady Cumberlege, for her original work on this, as well as now to the Patient Safety Commissioner. We are looking in detail at these issues and will continue to do so. I should make it clear, however, that should we make any changes to the legislation, it will require—as I understand it—primary legislation. It will not in any case be retrospective, so all we can do is look at products going forward. Obviously, patient safety is our primary concern and is absolutely at the forefront of our mind in taking these issues forward.